Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Annexon Biosciences ( (ANNX) ) has issued an announcement.
On June 5, 2025, Annexon, Inc. conducted its Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and financial oversight. During the meeting, two Class II directors, Jung E. Choi and William D. Waddill, were elected for a three-year term, and KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Additionally, the compensation of the company’s named executive officers was approved on an advisory basis.
The most recent analyst rating on (ANNX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Annexon Biosciences stock, see the ANNX Stock Forecast page.
Spark’s Take on ANNX Stock
According to Spark, TipRanks’ AI Analyst, ANNX is a Underperform.
Annexon Biosciences faces significant challenges typical of pre-revenue biotechnology companies. The lack of revenue and increasing financial losses are major concerns, despite strong cash reserves and low debt. Technical analysis indicates a bearish trend, and valuation metrics reflect the absence of profitability. Overall, the stock’s performance is constrained by financial and market challenges in a high-risk sector.
To see Spark’s full report on ANNX stock, click here.
More about Annexon Biosciences
Average Trading Volume: 1,802,367
Technical Sentiment Signal: Sell
Current Market Cap: $285.3M
See more data about ANNX stock on TipRanks’ Stock Analysis page.